Menu
POTENTIAL DEAL DETAILS
| Stock | Theseus Pharmaceuticals, Inc. | Symbol | THRX |
| Date Announced | 11/13/2023 | Source | Press Release |
| Type | Company Seeking Strategic Alternatives |
| Date of Confirmation: | 12/22/2023 | Price at Confirmation: | $3.70 |
| Potential Profit: | 15.26% | Annualized Profit: | 142.86% |
Theseus Pharmaceuticals, Inc. (THRX) a clinical-stage biopharmaceutical company announced that it is conducting a process exploring strategic alternatives to maximize shareholder value.
Update(s):
November 27, 2023:
On November 22, 2023, the board of directors of Theseus Pharmaceuticals received an unsolicited joint letter from Foresite Capital, LLC and OrbiMed Advisors LLC in which Foresite and OrbiMed indicated their intent to explore and evaluate a potential acquisition of all of the outstanding shares of common stock of the company not already owned by Foresite or OrbiMed in a going-private transaction.
On November 24, 2023, the Board also received an unsolicited proposal from Tang Capital Partners, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Theseus for $3.80 per share in cash, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of Theseus’ programs.
Theseus Pharmaceuticals, Inc. Investor Relations
Disclaimer: Our intent with this section of the website is to present potential deals that appear to be in the pipeline. These potential deals are ones where i) the company has indicated that it is "seeking strategic alternatives", ii) there has been an unsolicited bid for a company as mentioned in a press release by the company or iii) news about the deal has been published by a leading news organization like The Wall Street Journal, The New York Times, Bloomberg, Financial Times, The Washington Post, Reuters and The Associated Press. As best as possible we will try to avoid baseless rumors. There is a high probability that many of these potential deals may not materialize and if they do, the terms of the deal may be different from what was initially reported. Please do your own due diligence before buying or selling any securities mentioned on this website. We do not warrant the completeness or accuracy of the content or data provided.